tiprankstipranks
Trending News
More News >

Calliditas Therapeutics downgraded to Hold from Buy at Stifel

Stifel downgraded Calliditas Therapeutics to Hold from Buy with a price target of $40, down from $55, after Asahi Kasei offered about $40 per ADR in a takeover, which has been accepted by the boards of both companies. Though Calliditas was tracking toward profitability in the second half of 2024, the firm expects Asahi Kasei’s “deeper pockets should allow even greater engagement in the increasingly active IgAN field,” the analyst tells investors.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue